rs201106962
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 2P and 6B. PM1BP4_ModerateBS2
The NM_000345.4(SNCA):c.150T>G(p.His50Gln) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000182 in 1,613,152 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000345.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -4 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SNCA | NM_000345.4 | c.150T>G | p.His50Gln | missense_variant | 3/6 | ENST00000394991.8 | NP_000336.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SNCA | ENST00000394991.8 | c.150T>G | p.His50Gln | missense_variant | 3/6 | 1 | NM_000345.4 | ENSP00000378442 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000855 AC: 13AN: 152088Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000795 AC: 20AN: 251448Hom.: 0 AF XY: 0.0000441 AC XY: 6AN XY: 135904
GnomAD4 exome AF: 0.000192 AC: 280AN: 1461064Hom.: 1 Cov.: 29 AF XY: 0.000186 AC XY: 135AN XY: 726944
GnomAD4 genome AF: 0.0000855 AC: 13AN: 152088Hom.: 0 Cov.: 32 AF XY: 0.0000808 AC XY: 6AN XY: 74282
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2023 | SNCA: PS3:Supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Mar 23, 2023 | Published functional studies demonstrate a damaging effect leading to accelerated protein aggregation (Ghosh et al., 2013; Porcari et al., 2015; Rutherford et al., 2014); Reported in patients with dopa-responsive Parkinson disease in published literature (Appel-Cresswell et al., 2013; Proukakis et al., 2013); Reported as a somatic variant in brain tissue of an individual with sporadic late-onset Parkinson disease (Proukakis et al., 2013); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 26306801, 31980526, 29398121, 23669636, 26076669, 25330418, 26341711, 25554495, 24728187, 25505181, 24984882, 24936070, 25393002, 27573854, 30528390, 31996268, 23916651, 27250986, 23674458, 28650719, 24047453, 23674490, 23427326, 24315198, 23457019, 36099961) - |
Autosomal dominant Parkinson disease 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 08, 2014 | - - |
Lewy body dementia;C1868595:Autosomal dominant Parkinson disease 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 25, 2023 | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 50 of the SNCA protein (p.His50Gln). This variant is present in population databases (rs201106962, gnomAD 0.01%). This missense change has been observed in individual(s) with Parkinson's disease (PMID: 23427326, 23457019, 29398121). ClinVar contains an entry for this variant (Variation ID: 162095). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects SNCA function (PMID: 23427326, 30528390). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Parkinson Disease, Dominant Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jul 24, 2016 | The SNCA c.150T>G (His50Gln) missense variant has been reported in a heterozygous state in two individuals with Parkinson disease (Appel-Cresswell et al. 2013; Proukakis et al. 2014). Both individuals appeared to share a common haplotype, suggesting a possible founder effect. The p.His50Gln variant was absent from 1325 controls and is reported at a frequency of 0.00003 in the Total population of the Exome Aggregation Consortium. Functional studies demonstrated that the p.His50Gln variant did not significantly alter the structure of the protein but accelerated SNCA fibril aggregation and oligomerization (Ghosh et al. 2013; Khalaf et al. 2014). The variant was also shown to increase SNCA secretion, extracellular toxicity, and cell death (Khalaf et al. 2014; Petrucci et al. 2015). Based on the collective evidence, the p.His50Gln variant is classified as a variant of unknown significance but suspicious for pathogenicity for Parkinson disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Lewy body dementia;C1854182:Autosomal dominant Parkinson disease 4;C1868595:Autosomal dominant Parkinson disease 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Dec 06, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at